Researchers at the Johns Hopkins Kimmel Cancer Center have unveiled a promising new treatment approach for advanced HER2-negative breast cancer, using a three-drug combination that significantly improved responses in patients suffering from the disease. The study, published in Nature Cancer, involved a combination of a histone deacetylase (HDAC) inhibitor, which…

Investigators at the University of Illinois Chicago (UIC) have developed new data that show a commonly ordered breast cancer biomarker test to help clinicians decide whether breast cancer patients should receive chemotherapy may be making bad recommendations for some Black women who take the test. The test, The Oncotype 21-gene…

Researchers from the University of North Carolina have discovered that disrupting the cell’s innate immune response to DNA damage could be a mechanism of cancer resistance. In their paper in Nature, a team  proposes that the protein MRE11 could serve as a key in activating the cGAS-STING pathway, which is…

Patients with node-positive breast cancer that becomes node-negative after neoadjuvant chemotherapy can omit regional nodal irradiation (RNI) without increasing their risk for recurrence, suggests data presented at the 2023 San Antonio Breast Cancer Symposium. The de-escalation of treatment could spare a large proportion of patients the side effects associated with…

A groundbreaking study conducted at Northwestern Medicine suggests that an artificial intelligence (AI) tool could spare breast cancer patients unnecessary chemotherapy treatments by more accurately predicting patient outcomes. The research, published today in Nature Medicine, shows that the AI tool outperformed the analysis of disease by expert pathologists. While current…

City of Hope researchers have identified four metabolism-related biomarkers that may be associated with an increased risk for metastatic prostate cancer in men of West African heritage and could one day be incorporated into a disease prediction tool for this high-risk population. “We hope that our findings can become part…

Natera announced today that it received written confirmation from the Centers for Medicare & Medicaid Services (CMS) that its Signatera molecular residual disease (MRD) test will be reimbursed for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer. The coverage is available across all subtypes including…

The search to understand and treat cancer triggers a desire to look for the cause. For decades, many clinicians and scientists suggested that genes cause cancer. Siddhartha Mukherjee wrote in The Emperor of All Maladies: A Biography of Cancer, “Cancer, we have discovered, is stitched into our genome.” Indeed, cancer…

Researchers from the International Institute for Nanotechnology (IIN) at Northwestern University have combined chemistry and nanotechnology to change the structural location of adjuvants and antigens on and within a nanoscale cancer vaccine to boost potency and performance. Their method was published recently in Nature Biomedical Engineering. “Cancer vaccines must activate multiple…

Researchers at the Cancer Research UK Cambridge Institute at the University of Cambridge report that using mouse models they have developed a new technique for identifying the different types of cells in a tumor. The method allows tracking of tumor cells during treatment, to observe which types of cells die…

A potential therapeutic target for triple negative breast cancer (TNBC) has been pinpointed by researchers at Virginian Commonwealth University (VCU) Massey Cancer Center. Importantly, this target may be effective in black patients, who suffer disproportionally from the disease. Further, the researchers may have a lead on a biomarker—c-MYC—to guide treatment.…

A study by researchers from the Dana-Farber Cancer Institute provides novel insights into the high incidence of and risk factors for central nervous system metastases (mCNS) in women with inflammatory breast cancer. The findings “could have implications for surveillance and prognosis of the disease,” wrote Laura Warren, from the Department…

A team of researchers from King’s College London and The Institute of Cancer Research have identified immune cell types that could be targeted for treatment of post-neoadjuvant chemotherapy (NAC)–resistant triple-negative breast cancer (TNBC) and ER+ HER2- breast cancer. The research, published in Clinical Cancer Research, represented a “deep dive” into…

Researchers from the Garvan Institute of Medical Research have released research findings detailing how collagen type XII plays a role the regulation and organization of the cancer tumor matrix and also triggers breast cancer cells from the tumor to spread around the body. A potential application of this new finding,…

New immunotherapy treatments offer promise for an aggressive and difficult-to-treat form of breast cancer called triple negative breast cancer, but not all people have equal access to the treatments. Triple negative breast cancer makes up roughly 15% of all breast cancer in the general population, but in African American women…